Pharmacy & Biological SciencesCategory
Biopharma companies can balance competing demands from patients, investors, and regulators by keeping their focus on the science.
The task force is charged with identifying the reasons why some shortages remain a persistent challenge and to look for holistic solutions to addressing the underlying causes for these shortages.
Your best weapon to defeat the beast known as cancer is early detection. So, why is funding so focused on finding a “cure,” instead of screening?
An in-depth look at a recent paper that explores correlational data relating opioid prescribing to opioid manufacturer payments.
The increasing cost of Type 1 diabetes, one of the most common serious chronic diseases, has created heavy financial burdens for families, with insulin prices more than doubling in the past decade.
Take a look at highlights from 15 years of changes in biopharmaceutical manufacturing.
Only one in four Americans believes the U.S. government’s role in funding research is irreplaceable, according to a study by ScienceCounts.
The FDA established the Patient Engagement Advisory Committee in a move to broaden patient engagement and strengthen patients’ voice in regulatory activities.
The pharmaceutical industry fears major legislation that would curb prices and shrink profits, and has launched campaigns against it—but how honest are their claims?
The National Science Foundation recently issued 27 new grants totaling more than $8 million to promote “diversity and inclusion” in STEM fields.